GSK raises annual forecasts again on strong Arexvy launch

Analysts expect GSK's RSV vaccine Arexvy to power future growth, stemming worries about the strength of its pipeline of drugs in development and costly U.S. litigation over discontinued heartburn drug Zantac. Arexvy, launched in the United States recently, is expected to garner full-year sales of between 900 million pounds to 1 billion pounds ($1.22 billion), GSK said. The London-listed drugmaker said it now expects a rise of 17% to 20% in annual adjusted earnings per share, excluding the effect of currency swings, up from 14%-17% growth previously forecast.